share_log

百济神州BTK抑制剂百悦泽在中国获批滤泡性淋巴瘤适应症

Gelonghui Finance ·  May 13 04:31
格隆汇5月13日|百济神州宣布,其BTK抑制剂百悦泽(泽布替尼)获得中国国家药品监督管理局(国家药监局)附条件批准注册,新增以下适应症:联合奥妥珠单抗,适用于既往接受过至少二线系统性治疗的复发或难治性滤泡性淋巴瘤(FL)成人患者。
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment